Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation and Depletion (2020 - 2024)

Immuneering has reported Depreciation and Depletion over the past 5 years, most recently at $86116.0 for Q4 2024.

  • Quarterly results put Depreciation and Depletion at $86116.0 for Q4 2024, down 4.05% from a year ago — trailing twelve months through Dec 2024 was $355807.0 (up 10.22% YoY), and the annual figure for FY2024 was $355807.0, up 10.22%.
  • Depreciation and Depletion for Q4 2024 was $86116.0 at Immuneering, down from $88949.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for IMRX hit a ceiling of $90533.0 in Q2 2024 and a floor of $5656.0 in Q3 2020.
  • Median Depreciation and Depletion over the past 5 years was $68075.0 (2022), compared with a mean of $52121.7.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 468.33% in 2022 and later decreased 4.05% in 2024.
  • Immuneering's Depreciation and Depletion stood at $7449.0 in 2020, then surged by 98.89% to $14815.0 in 2021, then skyrocketed by 418.81% to $76862.0 in 2022, then grew by 16.77% to $89754.0 in 2023, then fell by 4.05% to $86116.0 in 2024.
  • The last three reported values for Depreciation and Depletion were $86116.0 (Q4 2024), $88949.0 (Q3 2024), and $90533.0 (Q2 2024) per Business Quant data.